Nasus Pharma (NSRX) investor relations material

Platform technology and pipeline

• Proprietary powder-based intranasal delivery enables multiple differentiated therapies in acute and emergency medicine.

• Lead product is a powder intranasal epinephrine for anaphylaxis, with phase III trials starting Q4 this year and NDA submission targeted for mid-2027.

• Additional pipeline includes intranasal ondansetron for chemotherapy-induced nausea and other undisclosed programs entering the clinic this year.

• All programs are expected to reach significant milestones within the next 6-12 months.

• Broad intellectual property protection extends to 2038, covering both platform and individual products.

Clinical data and competitive differentiation

• Phase II data show powder epinephrine achieves therapeutic plasma levels in half the time of EpiPen (1.7 vs. 3.5 minutes), with 88% of patients reaching threshold at 5 minutes versus 64% for EpiPen.

• Product maintains efficacy and absorption even under nasal congestion, outperforming liquid competitors.

• Superior onset and absorption confirmed in both single and repeat dosing, with no serious adverse events and only mild, self-resolving local effects.

• Market research indicates onset of action is the primary decision driver for physicians choosing between needle-free epinephrine options.

• Market cap is significantly lower than competitors despite best-in-class data, presenting a perceived valuation gap.

Market opportunity and strategic positioning

• Anaphylaxis market estimated at $2.5 billion and growing, with 20 million at-risk patients in the US but only 7 million prescriptions for EpiPen.

• Needle phobia and device inconvenience limit EpiPen adoption and adherence, creating opportunity for needle-free, compact alternatives.

• Competitors include ARS Pharma (liquid intranasal, approved) and Aquestive (sublingual, pending resubmission), but powder formulation offers faster onset and better absorption.

• Competitor investments in education and reimbursement are expected to benefit future entrants by raising awareness and access.

• Multiple upcoming clinical and regulatory milestones expected to drive value over the next year.